
    
      The study will have the following sequential phases for all subjects:

        -  Screening

        -  Pre-Treatment (Cell Product Preparation and Lymphodepleting Chemotherapy)

        -  Treatment and Follow-up Tisagenlecleucel infusion should occur within 16 weeks of
           informed consent. The total duration of the study is 5 years. After tisagenlecluecel
           infusion, efficacy will be assessed monthly for the first 6 months, then quarterly up to
           2 years and semi-annually afterwards up to 5 years, or until the subject relapses.
    
  